ArticleBreast cancer research and treatment2016
A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).
Article in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Experience of women with breast cancer undergoing chemotherapy: a systematic review of qualitative research.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study.Journal of the National Cancer Institute · 2026Article
- Completion vs. early discontinuation of chemotherapy and the impact on 5-year all-cause mortality in women treated for early-stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach.British journal of clinical pharmacology · 2026Article
- The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.Cancer · 2026Article
- Heterogeneity in benefit finding among breast cancer patients: a latent profile analysis and influencing factors.Frontiers in oncology · 2026Article
- Evaluating the effect of using a mobile app on the management of chemotherapy side effects and quality of life in breast cancer patients: Protocol for a randomized controlled trial.Journal of education and health promotion · 2026Article
- Identifying Core Symptoms in Breast Cancer Patients with Different Chemotherapy Phases Using Network Analysis: A Prospective Multicenter Longitudinal Study.Patient preference and adherence · 2026Article
- Determinants of chemotherapy abandonment in Ethiopia: a nested case-control study.The oncologist · 2025Article
- Article
- Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors.Breast cancer research and treatment · 2022Article
- Adherence to Chemotherapy among Women with Breast Cancer Treated at Tikur Anbessa Specialized and Teaching Hospital, Addis Ababa, Ethiopia.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Tailoring the Evidence for Exercise Oncology within Breast Cancer Care.Current oncology (Toronto, Ont.) · 2022Review
- Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.Breast cancer research and treatment · 2022Article
- Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial.Contemporary clinical trials · 2021Article
- Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy.JAMA network open · 2021Article
- Impact of patients' refusal to undergo adjuvant treatment measures on survival.Breast cancer research and treatment · 2021Article
- Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.Cancer · 2020Article
- Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.The oncologist · 2019Article
- Article
- Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
For many women with non-metastatic breast cancer, adjuvant chemotherapy prevents recurrence and extends survival. Women who discontinue chemotherapy early may reduce those benefits, but little is known about what predicts early discontinuation. We sought to determine prospectively the rate and reasons for early discontinuation of adjuvant chemotherapy in women with breast cancer. We conducted a prospective cohort study among three U.S. health care organizations. Of 1158 women with newly diagnosed non-metastatic breast cancer, 2006-2010, we analyzed 445 (38.4 %) patients who initiated standard adjuvant chemotherapy as defined by accepted guidelines. We interviewed patients at baseline and twice during treatment regarding sociodemographic/psychosocial factors and treatment decision-making and collected clinical data. They were categorized according to the number of cycles required by the chemotherapy regimen they had initiated. The outcome was early discontinuation (<80 % of planned cycles). Of patients analyzed, 392 (88.1 %) completed the prescribed therapy. The strongest predictor was receipt of a regimen entailing >4 cycles of therapy (18.1 % for longer regimens, 7.4 % for 4 cycles) (odds ratio [OR] 2.59, 95 % CI 1.32-5.08), controlling for race, age, stage, hormone receptor status, social support, optimism, spirituality, stress, and physical symptoms. Higher levels of psychological symptoms on the Memorial symptom assessment scale also increased the odds of early discontinuation (OR 1.92, 95 % CI 0.998-3.68). The large majority of patients who initiated adjuvant chemotherapy for breast cancer completed their prescribed regimens, but early discontinuation was associated with lengthier regimens and, with borderline statistical significance, for those with psychological side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.